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Summary 
The relationship between protein Z levels and thrombosis is controver-
sial. We performed a systematic review and meta-analysis of the avail-
able studies to assess the association between protein Z and vascular 
thrombotic diseases. We conducted an electronic literature search 
through MedLine, Embase, Google Scholar, Web of Science, The Coch-
rane Library, bibliographies of retrieved articles and abstracts of con-
gresses up to October, 2009. Studies were included if they analysed pro-
tein Z levels in patients with vascular thrombotic diseases. After the re-
view process, 28 case-control studies (33 patient cohorts), including 
4,218 patients with thrombotic diseases and 4,778 controls, were se-
lected for analysis. The overall analysis using a random-effects model 
showed that low protein Z levels were associated with an increased risk 
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of thrombosis (odds ratio [OR] 2.90, 95% confidence interval [CI] 
2.05–4.12; p<0.00001). On subgroup analysis, a significant association 
was found between low protein Z levels and arterial vascular diseases 
(OR 2.67, 95%CI 1.60–4.48; p=0.0002), pregnancy complications (OR 
4.17, 95%CI 2.31–7.52; p<0.00001), and venous thromboembolic dis-
eases (OR 2.18, 95%CI 1.19–4.00; p=0.01). The results of this meta-
analysis are consistent with a role for protein Z deficiency in thrombotic 
diseases, including arterial thrombosis, pregnancy complications and 
venous thromboembolism.  
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Introduction 
Protein Z is a vitamin K-dependent plasma glycoprotein described 
in its human form in 1984 (1). The amino acid sequence of protein 
Z shows wide homology with many coagulation factors, such as 
VII, IX, X, and protein C (2). In contrast to many other vitamin 
K-dependent coagulation factors, however, protein Z is not a zy-
mogen of a serine protease (2). The physiological function of pro-
tein Z was uncertain for many years until in vitro and in vivo studies 
demonstrated that protein Z plays an important role in inhibiting 
coagulation, serving as a cofactor for the inactivation of activated 
factor X by plasma protein Z-dependent protease inhibitor (3).  
The potential role of alterations of protein Z levels in the patho-
genesis of thrombotic diseases has been evaluated in several studies 
that have produced conflicting findings (4–32). On one side, many 
of the clinical studies reported low protein Z levels to be associated 
with the occurrence and progression of several types of ischaemic 
vascular diseases, such as ischaemic stroke, coronary heart disease, 
venous thromboembolic diseases and fetal loss (5, 7, 8, 10–12, 14, 
17, 19, 21, 23, 25–29, 31), whereas, on the other side, some studies 
either did not observe an association or reported an association be-
tween high, instead of low, levels of protein Z and thrombotic dis-
ease (6, 9, 13, 15, 16, 18, 20, 22, 24, 30, 32). 
In order to evaluate this complex issue, we systematically re-
viewed and analysed all the available studies addressing the poten-
tial association of protein Z levels with the risk of thrombosis. 
Methods 
Selection of studies 
Studies that investigated the possible association between protein 
Z and an increased risk of thrombosis in adults were identified 
through a computerised search in all the electronic databases: 
MedLine (source: PubMed, 1966 to October 2009), Embase (1980 
to October 2009), Web of Science, The Cochrane Library (source: 
The Cochrane Central Register of Controlled Trials, 2009, issue 1), 
Clinicaltrials.org, and Google Scholar. Relevant keywords relating 
to protein Z in combination as MeSH terms and text words (“pro-
tein Z”, “Z protein”, “vitamin K-dependent protein”, “vitamin K-de-
pendent glycoprotein” or “blood protein”) were used in combination 
with words relating to thrombosis (“thrombosis”, “haemostasis”, 
“thrombotic diseases”, “venous thrombosis”, “venous thromboembol-
ism”, “arterial thrombosis”, “atherothrombosis”, “vascular diseases”, 
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“embolism”, “cardiovascular disease”, “cerebrovascular disease”, 
“stroke”, “peripheral arterial disease”, “pregnancy”, “fetal loss”, “blood 
coagulation”, or “coagulation disorders”). The search strategy had 
no language restrictions and was supplemented by manually re-
viewing the reference list of all retrieved articles as well as abstracts 
from the congresses of the International Society on Thrombosis 
and Haemostasis (ISTH), American Society of Haematology 
(ASH), American Heart Association (AHA), American College of 
Cardiology (ACC), and European Society of Cardiology (ESC) to 
October, 2009. 
Two investigators (FS, FC) assessed potentially relevant articles 
for eligibility. The decision to include or exclude studies was hier-
archical and initially made on the basis of the study title, then of the 
study abstract, and finally of the complete study manuscript. In the 
event of conflicting opinions, resolution of the disagreement was 
resolved through discussion. Eligible studies were included if they 
met all of the following criteria: (i) conducted on adults (i.e. older 
than 18 years); (ii) evaluated patients with thrombotic events; and 
(iii) presented data on protein Z levels and on cut-off levels of pro-
tein Z in relation to the disease. Accordingly, studies were excluded 
if they were not conducted in humans, if they considered outcomes 
different from those of interest for the meta-analysis, if they failed 
to report concentrations of protein Z for cases and control sub-
jects, if they did not report proportions of patients with abnormal 
protein Z levels or if they failed to present estimates of association 
with the disease. 
Outcomes of interest for the current meta-analysis were vascu-
lar thrombotic diseases, and included arterial vascular diseases 
such as cerebro- and cardio-vascular diseases, peripheral arterial 
disease, ischaemic colitis, and retinal thrombosis, pregnancy com-
plications such as fetal loss, and preeclampsia as well as venous 
thromboembolic diseases such as deep-vein thrombosis, venous 
thromboembolism, pulmonary embolism, portal vein thrombo-
sis, and retinal vein occlusion. 
Data extraction 
All data were reviewed and separately extracted by two indepen-
dent investigators (FS, FC) using a standardised form. The follow-
ing baseline characteristics were collected: author’s name and 
country of the study patients, number of patients, mean age of the 
study populations, gender, type of disease, cut-off levels of protein 
Z, number of patients and controls with altered protein Z values, 
odds ratios (OR) and confidence intervals (CI), as well as adjust-
ment for confounding factors in multivariate analysis.  
Statistical analysis 
Review Manager (RevMan; version 5.0.18 for Macintosh; Copen-
hagen, Denmark; The Cochrane Collaboration, 2008) was used to 
pool results from the individual studies.  
Pooled results are reported as OR and are presented with 95%CI 
with two-sided p-values using both a fixed-effects model (Mantel-
Haenszel method) and a random-effects model (DerSimonian and 
Laird method). The two models yielded very similar estimates. 
Therefore, we decided to present the results based on the random-
effects model because of the presence of significant heterogeneity 
in the analyses. A p-value less than 0.05 was considered statistically 
significant. The results of the original studies using multivariate 
models with the most complete adjustment for potential con-
founders were used when available; the confounding variables in-
cluded in these analyses are shown in the Supplementary data (see 
Supplementary data available online at www.thrombosis-online.
com). When not provided, estimates of an association were calcu-
lated using the number of patients and controls with abnormal 
protein Z levels. For studies reporting high, instead of low, protein 
Z levels to be associated with an increased risk of thrombosis, we 
recalculated the OR, by using conventional procedures. 
Statistical heterogeneity was evaluated using the I2 statistic, 
which assesses the appropriateness of pooling the individual study 
results. The I2 value provides an estimate of the amount of variance 
across studies due to the heterogeneity rather than chance.  
Where I2 was greater than 50%, heterogeneity was considered 
substantial. Moreover, to further investigate the heterogeneity 
across the studies we performed sensitivity analyses by dividing 
studies into groups according to their main characteristics. Sub-
group analyses were then performed according to mean sample 
size of the patient population (<128; >128), to the country of ori-
gin of the patients (European countries; non-European countries), 
to the mean age of the patients’ populations (<45 years; >45 years), 
as well as to the presence or absence of adjustment for possible 
confounding factors (yes; no). Small study bias and/or publication 
bias was appraised by visual inspection of funnel plot of effect size 
against standard error and, analytically, by the Egger’s test. 
Results 
Study identification and selection 
Our search strategy yielded 158 articles (Fig. 1). Of these 56 ar-
ticles were excluded either because they were not conducted on hu-
mans or because they were reviews or reports of case studies. The 
selected articles were carefully reviewed and a further 38 articles 
were excluded because they did not include patients with out-
comes of interest. Thirty-four additional studies were excluded be-
cause they reported no data on protein Z levels (n=23) or cut-off 
levels of protein Z for an increased risk of disease (n=11). Finally, 
one study was excluded because it lacked a control group and one 
because it was a study aimed at testing the efficacy of thrombopro-
phylaxis in women with an unexplained previous pregnancy loss.  
As a result, 28 case-control studies were included and entered 
into the final analysis. Of these, five papers reported different co-
horts of patients for separate clinical outcomes. Therefore, as a 
whole, 33 groups of patients were analysed. Included studies 
ranged in size from 16 to 443 cases and from 31 to 593 controls, for 
a total number of 4,218 patients and 4,778 controls.  
Characteristics of the studies included in the meta-analysis are 
summarised as supplementary data (see Supplementary data avail-
able online at www.thrombosis-online.com). Most were con-
ducted in European countries. The vast majority of the studies in-
vestigated low protein Z levels in association with an increased risk 
of thrombosis (5, 7, 8, 10–12, 14–23, 25–32), whereas four studies 
evaluated the opposite hypothesis, i.e. whether high protein Z lev-
els were associated with an increased risk of thrombotic events (6, 
9, 13, 24). Therefore, the cut-off levels for the proposed abnormal 
protein Z levels differed substantially among the included studies, 
ranging from < 520 ng/ml to > 2,600 ng/ml. In three out of 28 
studies protein Z levels were measured in terms of percentage valu-
es and not as absolute levels (6, 18, 31). Moreover, a multivariate lo-
gistic regression model was tested only in some (n=10) of the in-
cluded studies, with significant differences in the variables used to 
adjust the analyses (6, 12, 13, 19, 22, 23, 26–28, 31). 
Meta-analysis 
Meta-analytic pooling under a random-effects model showed that 
patients with low protein Z levels are at increased risk of throm-
botic events (OR 2.90, 95%CI 2.05–4.12; p<0.00001) (Fig. 2). 
However, significant statistical heterogeneity across the studies 
(I2=80%) was detected. When studies evaluating different clinical 
outcomes were grouped, we found that low protein Z levels were a 
significant risk factor for arterial vascular diseases (n=18 reports, 
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Figure 1:  
Flow chart of 
search strategy. 
with a total of 2,054 patients and 3,033 controls) (OR 2.67, 95%CI 
1.60–4.48; p=0.0002) (Fig. 3), pregnancy complications (n=8 
reports, with a total of 714 patients and 515 controls) (OR 4.17, 
95%CI 2.31–7.52; p<0.00001) (Fig. 4), and venous thromboem-
bolic diseases (n=8 reports, with a total of 1,297 patients and 1,399 
controls) (OR 2.18, 95%CI 1.19–4.00; p=0.01) (Fig. 5). Table 
1 reports all the results according to both fixed and random mod-
els. Significant statistical heterogeneity across the studies was also 
noted in the subgroup analyses: I2=82% for the outcome of arter-
ial vascular diseases; I2=69% for the outcome of pregnancy com-
plications, and I2=70% for the outcome of venous thromboem-
bolic diseases.  
Sensitivity analyses 
In order to analyse the nature of this heterogeneity across the 
studies we performed sensitivity analyses by grouping studies ac-
cording to characteristics such as size of the studies (mean size of 
the patients sample: 128), country of origin of the patients (Euro-
pean countries versus other countries), age of the patients (mean 
age: 45) and adjustment for confounding factors at the multivari-
ate analysis (yes; no) (Fig. 6). Studies conducted on patients with 
an age above the mean age of all the population of patients (>45 
years) and smaller studies showed a tendency towards a more elev-
ated estimate of association with the increased risk of thrombosis 
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Figure 2: Risk of vascular thrombotic diseases for low protein Z levels. Squares represent the effect size; extended lines, 95%CI; diamond, total ef-
fect size. IS, ischaemic stroke; DVT, deep-vein thrombosis; ACS, acute coronary syndromes; CAD, coronary artery disease; PE, preeclampsia; FL, fetal loss; ART, 
arterial vascular diseases; VEN, venous thromboembolic diseases. 
with respect to those conducted in younger patients and to larger 
studies. 
In addition, we conducted multiple leave-one-out analyses for 
the secondary endpoints. Specifically, we found that the studies by 
Kobelt et al. (6), McQuillan et al. (13), and Morange et al. (16), were 
the major contributors to statistical heterogeneity in the analysis 
for arterial vascular diseases (p for heterogeneity from 0.00001 
overall to 0.19 after their exclusions, with I2 going from 82% to 
24%) whereas the studies by Bretelle et al. (21), and Erez et al. (25), 
were the main contributors to statistical heterogeneity for preg-
nancy complications (p for heterogeneity from 0.002 overall to 
0.17 after their exclusions, with I2 going from 69% to 35%). The 
© Schattauer 2010 Thrombosis and Haemostasis 103.4/2010
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Figure 3: Risk of arter-
ial vascular diseases 
for low protein Z lev-
els. Squares represent 
the effect size; extended 
lines, 95%CI; diamond, 
total effect size. IS, is-
chaemic stroke; ACS, 
acute coronary syn-
dromes; CAD, coronary 
artery disease; ART, arter-
ial vascular diseases. 
Figure 4: Risk of preg-
nancy complications 
for low protein Z lev-
els. Squares represent 
the effect size; extended 
lines, 95%CI; diamond, 
total effect size. PE, pre-
eclampsia; FL, fetal loss.  
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Figure 5: Risk of ve-
nous thromboembolic 
diseases for low pro-
tein Z levels. Squares 
represent the effect size; 
extended lines, 95%CI; 
diamond, total effect 
size. 
studies by Kemkes-Matthes et al. (8), and Pardos-Gea et al. (27) 
were the main contributors to statistical heterogeneity for venous 
thromboembolic disease (p for heterogeneity from 0.002 overall to 
0.28 after their exclusion, with I2 going from 70% to 22%).  
Interestingly, however, none of these exclusions led to loss of 
statistical significance in favour of low protein Z levels as a predis-
posing factor in the occurrence of thrombosis.  
Publication bias 
The funnel plots of effect size versus standard error, performed in 
order to investigate for a possible publication bias, were broadly 
asymmetric (see Supplementary data available online at www.
thrombosis-online.de), suggesting the presence of some statistical 
outliers among the included studies (Egger’s test: p<0.0001). After 
the exclusion of the studies that contributed substantially to the 
heterogeneity of the results, however, publication biases were not 
Figure 6: Subgroup 
analyses. Squares repre-
sent the effect size; ex-
tended lines, 95%CI; dia-
mond, total effect size. 
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Table 1: Results of fixed and random models.
Outcome (n, reports) Patients, n Controls, n Fixed model Random model 
OR (95%CI) I2; p (het.) OR (95% CI) I2; p (het.) 
All outcomes (33) 4,218 4,778 1.87 (1.62–2.15) 80%; p<0.0001 2.90 (2.05–4.12) 80%; p<0.0001 
Arterial vascular events (18) 2,054 3,033 1.86 (1.51–217) 82%; p<0.0001 2.67 (1.60–4.48) 82%; p<0.0001 
Pregnancy complications (8) 714 515 3.42 (2.51–4.66) 69%; p=0.002 4.17 (2.31–7.52) 69%; p=0.002 
Venous thromboembolic 
diseases (8) 
1,297 1,399 1.28 (1.01–1.65) 70%; p=0.002 2.18 (1.19–4.00) 70%; p=0.002
detected based on the p-value of the Egger’s test (p=0.08 for the 
outcome of vascular arterial diseases; p=0.2 for the outcome of 
pregnancy complications; and p=0.3 for the outcome of venous 
thromboembolic diseases).  
Discussion 
This is the first systematic review with meta-analysis conducted to 
evaluate the role of protein Z on the occurrence of thrombosis-re-
lated clinical outcomes. All the available studies on protein Z and 
clinical thrombotic events were systematically reviewed and separ-
ated into three different clinical outcomes, arterial vascular dis-
eases such as ischaemic stroke, coronary heart disease, peripheral 
arterial disease or other ischaemic events involving the arteries, 
pregnancy complications such as fetal loss and preeclampsia, and 
venous thromboembolic diseases. This search strategy allowed us 
to analyse the role of protein Z in an overall population of more 
than 4,000 patients with thrombotic events as compared to control 
subjects. 
In this meta-analytical study, low levels of protein Z were found 
to be a significant risk factor for all the thrombotic events, for arter-
ial thrombosis, pregnancy complications and venous thromboem-
bolic diseases. Overall, patients with low levels of this coagulation 
regulatory protein show nearly a three-fold increased risk of 
thrombotic events with respect to control subjects. 
An association between protein Z deficiency and thrombosis 
has been demonstrated in animal models (33, 34), but human 
studies have produced conflicting results (5–32). Indeed, in four of 
these studies high circulating levels of protein Z were found to be 
associated with an increased risk of disease (6, 9, 13, 24). Although 
the aim of the present study was to determine whether low protein 
Z levels were a significant risk factor for the occurrence of throm-
bosis, these four studies were included in our analysis by comput-
ing estimates of association in a reverse way. By analysing sub-
groups of studies according to the clinical outcome, we were able to 
identify some studies as statistical outliers for the present meta-
analysis. For arterial thrombotic events, these were the studies by 
Kobelt et al. (6), and McQuillan et al. (13), that represent two out 
of the three studies that investigated the role of high levels of pro-
tein Z in relation to the clinical events, and the study by Morange et 
al. (16) that is a cohort prospective study, but used as a nested case-
control study for the aim of this meta-analysis. Acute, rather than 
convalescent protein Z levels were measured in one of these studies 
(13). Similarly, the main contributors for heterogeneity among 
pregnancy complication studies were those conducted by Bretelle 
et al. (21) and Erez et al. (25) that investigated preeclampsia as 
main clinical outcome and, for venous thromboembolic diseases, 
the studies by Kemkes-Matthes et al. (8) and Pardos-Gea et al. (27) 
that included either patients with positivity for factor V Leiden 
mutation or patients with venous thromboses in different locali-
sations. 
Subgroup analysis demonstrated a significant association be-
tween low protein Z and arterial vascular diseases (mainly is-
chaemic stroke and atherosclerotic vascular diseases), pregnancy 
complications (fetal loss and preeclampsia), and venous throm-
boembolic diseases (mainly deep-vein thrombosis). The link be-
tween protein Z and arterial disease is supported by the observa-
tion of protein Z in the atherosclerotic vascular lesions and the in-
teraction between protein Z and certain arterial risk factors (35, 
36). With regard to venous thromboses, on the other hand, signifi-
cant associations were reported particularly when accompanied 
with other acquired or genetic risk factors for thrombosis such as 
factor V Leiden mutation (8).  
Actually, the reasons why protein Z levels are decreased in pa-
tients with clinical manifestations of thrombotic diseases are dif-
ferent and not yet determined. One possibility could be that the 
persistent activation of the coagulatory process is able to deter-
mine an increased consumption of such protein. Another possibil-
ity could be that protein Z is reduced in its synthesis by liver and/
or by other sources such as endothelial cells. A further option can 
be that related to the presence of anti-protein Z antibodies and an-
other possibility could be the association between protein Z and 
some traditional risk factors. In addition, another explanation 
could reside on the association with the inflammatory state present 
in such kind of patients. All these hypotheses, together with a pos-
sible influence of medical therapies, might explain the variability 
observed in the present meta-analysis.  
Some limitations can be identified in the present study. First, 
the meta-analysis was performed on case-control studies and most 
of the included studies were of small size, thus the overall results 
have to be interpreted carefully. Second, the overall and the sub-
group results showed a moderate heterogeneity across the studies. 
Consistent results were obtained, however, following sensitivity 
and multiple leave-out-one analyses. Third, the possibility of pub-
lication bias cannot be fully eliminated despite the lack of evidence 
for such on funnel plot and Egger’s test performed after the exclu-
sion of outlier studies.  
In conclusion, the present meta-analysis conducted on 28 case-
control studies and 33 cohorts of patients, with an overall popu-
lation of more than 8,000 subjects, demonstrated that low protein 
Z levels are significantly associated with all thrombotic events, ar-
terial thromboses, pregnancy complications, and venous throm-
boembolic diseases. Additional issues concerning protein Z, how-
ever, still need to be addressed and clarified: the need of prospec-
tive and larger studies, whether protein Z is influenced by the acute 
phase response, the best method of protein Z measurement, and 
the optimal cut-off value for protein Z in the estimation of throm-
botic risk. 
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What is known about this topic? 
● Protein Z is a vitamin K-dependent glycoprotein whose sequence 
has wide homology with many coagulation factors. 
● Many studies have investigated the possible role of protein Z on 
the occurrence of thrombotic diseases. 
● The relationship between protein Z and thrombosis remains, how-
ever, controversial. 
What does this study add? 
● Low levels of protein Z are significantly associated with thrombotic 
diseases including arterial, venous thromboses as well as pregnan-
cy complications.
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